My Profile   |   Print Page   |   Contact Us   |   Sign In   |   Register
ASAP Blog
Blog Home All Blogs
Welcome to ASAP Blog, the best place to stay current regarding upcoming events, member companies, the latest trends, and leaders in the industry. Blogs are posted at least once a week; members may subscribe to receive notifications when new blogs are posted by clicking the "Subscribe" link above.

 

Search all posts for:   

 

Top tags: alliance management  collaboration  alliances  partnering  alliance  alliance managers  partners  alliance manager  partner  partnerships  ecosystem  The Rhythm of Business  governance  Jan Twombly  partnership  Strategic Alliance Magazine  Eli Lilly and Company  IoT  Vantage Partners  biopharma  Healthcare  NetApp  2015 ASAP Global Alliance Summit  ASAP BioPharma Conference  Cisco  IBM  innovation  strategy  Christine Carberry  communication 

The Virtuous Cycle in Alliance Management—a Summit Spotlight Exclusive (Part 2)

Posted By Cynthia B. Hanson, Tuesday, March 5, 2019
Updated: Monday, March 4, 2019

“The alliance manager’s role is to understand the importance of timing,” advises Christine Carberry, CSAP, in Part One of ASAP Media’s interview with the seasoned alliance manager and former chief operating officer of Keryx Biopharmaceuticals (now a subsidiary of Akebia Therapeutics). Carberry, who also previously served as chair of the ASAP board of directors, will be providing a leadership spotlight plenary session, “Collaborate-Create: The Value of the Virtuous Cycle,” at the 2019 ASAP Global Alliance Summit, “Agile Partnering in Today’s Collaborative Ecosystem,” March 10-13 at the Westin Fort Lauderdale Beach Resort in Fort Lauderdale, Florida. ASAP Media’s conversation with Carberry continues below.

Carberry’s role for six months of her year working for Keryx was as co-leader of integration planning with counterpart Akebia. Early on, she realized that her role wouldn’t continue with the new organization. She is philosophical about it. “You are working on trying to have everybody see the value of the merger—employees in the companies, investors, and shareholders. Yet people know you are not going to be part of it,” she explains of the challenge. “It’s about taking the time, if you can, to explore and not think that you have to jump right back into doing exactly what you were doing. Each experience leads to another.”

Alliance mangers are seekers of “the high road” trying to rise above conflict and egos, and keeping everyone focused on the common goal.  “You’re really a navigator,” she adds. “One of the criticisms that we’ve heard is alliance managers need to think of themselves much more broadly. And think of themselves as the people always looking for a portfolio of alliances and expanding value, not just be within the confines of agreements that you have today. That’s the challenge I want to give to the audience [at the Summit] in thinking about how we can have a greater impact by making better, stronger connections between ideas and resources, creating better conditions for collaboration. Your alliance portfolio is dynamic, and I think that alliance managers can create more value by really understanding that one alliance is one piece of a company portfolio and needs to align with company strategy.”

Before her one-year stint with Keryx, Carberry spent three and a half years with FORUM Pharmaceuticals (formerly EnVivo Pharmaceuticals) and 26 years with Biogen, where she stated out in an entry-level position during a time when genetic engineering was “scary science.” Biogen was a Fortune 500 international company that brought several drugs to patients “that changed their lives,” she adds. 

Despite being in transition between jobs, Carberry has “a very full plate.” In addition to her spotlight plenary session, as chairman emerita of ASAP, she will attend the Summit board and advisory meetings and will lead a roundtable about alliance management in a crisis situation. “It’s similar to what I’ve done in other transitional periods. It allows me to increase involvement in leadership roles,” she says.

Learn about Carberry’s talk and other leadership sessions and register for the 2019 ASAP Global Alliance Summit at http://asapsummit.org. See the ASAP Media team’s comprehensive before, during, and after coverage of the 2019 Summit in Strategic Alliance publications and on the ASAP blog.  

Tags:  Akebia Therapeutics  Alliance Excellence Award  alliance manager  Christine Carberry  conflict  digital  expanding value  Keryx Biopharmaceuticals  partnership  Patheon  strategic partner  technology  Thermo Fisher 

Share |
PermalinkComments (0)
 

The Virtuous Cycle in Alliance Management—a Summit Spotlight Exclusive (Part 1)

Posted By Cynthia B. Hanson, Tuesday, March 5, 2019
Updated: Monday, March 4, 2019

“There is a time and purpose for everything. So the alliance manager’s role is to understand the importance of timing.” Thus advises Christine Carberry, CSAP, a seasoned alliance manager and former chief operating officer of Keryx Biopharmaceuticals (now a subsidiary of Akebia Therapeutics). Carberry, who also previously served as chair of the ASAP board of directors, will be providing a leadership spotlight session “Collaborate-Create: The Value of the Virtuous Cycle” at the 2019 ASAP Global Alliance Summit, “Agile Partnering in Today’s Collaborative Ecosystem,” March 10-13 at the Westin Fort Lauderdale Beach Resort in Fort Lauderdale, Florida.

A virtuous cycle connects right ideas with right resources in the right timing, she continues. “Timing is part of creating the right environment for collaboration and pulling those pieces together and then generating value,” Carberry explains. “That value often generates new ideas that just feed back into it. Growing new ideas may mean you need different kinds of resources. You may have an idea on how to improve a patient’s experience in a clinical trial. From that, you may come up with an idea that there’s a way to make that experience better using technology. Now you need different resources and skillsets to improve the patient experience in a digital way.”

Carberry’s talk is based on 30 years of management experience. Right now, she is between companies after Keryx Biopharmaceuticals and Akebia Therapeutics merged in December. The two companies are under consideration for a 2019 ASAP Alliance Excellence Award for their handling of a supply disruption where patients could not obtain a jointly manufactured drug. Access resumed after the companies teamed togetherfrom the C-level to the operational teamsto create a quick, viable solution.  

 

 “We had to navigate this partnership when Patheon merged with Fisher, and Keryx with Akebia,” Carberry explains. “Traditionally, biopharma companies treat CMOs as vendors, not as collaborators. … Applying all of the ASAP approaches and tools to the CMO I think creates a much stronger partnership, and it was demonstrated in this supply disruption situation. We needed high levels of trust with CEO engagement. It wasn’t business as usual. It was requiring people to go above and beyond,” she continues. “Agile is a good word for it. That willingness to be flexible and agile is less likely to happen if you are treating your CMO as a vendor rather than as strategic partner. “

 

See the ASAP Blog for Part Two of this interview with Christine Carberry, CSAP. Learn about Carberry’s plenary talk and other leadership sessions at the 2019 ASAP Global Alliance Summit, and register for the event, at http://asapsummit.org. See the ASAP Media team’s comprehensive before, during, and after coverage of the 2019 Summit in Strategic Alliance publications and on the ASAP blog.  

Tags:  Akebia Therapeutics  Alliance Excellence Award  alliance manager  Christine Carberry  digital  Keryx Biopharmaceuticals  partnership  Patheon  strategic partner  technology  Thermo Fisher 

Share |
PermalinkComments (0)
 

Leaders ‘in a Time of Rapid Growth and Change’: Finalists for Announced for 2019 ASAP Alliance Excellence Awards

Posted By Noel B. Richards, Friday, February 15, 2019

Finalists Include Alcon Laboratories, Science Applications International Corporation, Keryx Biopharmaceuticals (subsidiary of Akebia Therapeutics), Thermo Fisher Scientific, Merck & Co., Merck KGaA, Darmstadt, Germany, Bristol-Myers Squibb, Cambridge Assessment English, Novartis, Incyte, Sanofi Pasteur, and Red Hat 

ASAP will honor companies and organizations, practices, and programs that exemplify exceptional performance in alliance management during the ASAP Alliance Excellence Awards ceremony at the 2019 ASAP Global Alliance Summit, which runs March 11-13 at the Westin Fort Lauderdale Beach Resort in Fort Lauderdale, Florida. This month, ASAP announced the companies that are 2019 Alliance Excellence Awards finalists: Alcon Laboratories, Science Applications International Corporation (SAIC), Keryx Biopharmaceuticals (now a subsidiary of Akebia Therapeutics), Thermo Fisher Scientific, Merck & Co., Merck KGaA, Darmstadt, Germany, Bristol-Myers Squibb, Cambridge Assessment English, Novartis, Incyte, Sanofi Pasteur, and Red Hat. See the official press release issued via PRWeb.

“This remarkable group of companies has demonstrated significant leadership in alliance management during a time of rapid growth and change for business—and for the partnering profession,” said Michael Leonetti, president & CEO of ASAP. “Our awards committee reviewed a number of outstanding nominees from diverse industries this year, and we’re pleased to recognize these exceptional partners and programs whose success stories and practices can serve as models for the alliance management community.”

Alcon Laboratories’ alliance program contains a complete set of fully documented best practices supported by information technology tools. With a small alliance group, they manage many partners through consistency applying these practices and tools.

 

Science Applications International Corporation (SAIC) has developed an alliance program covers not only the “hard” alliance elements, but also pays attention to the “softer” rules of the game, resulting in substantial contribution to revenues as well as recognition from partners. Partner tiering is consistently worked out across the strategic, financial, and relational elements of business.

 

Keryx Biopharmaceuticals (now a subsidiary of Akebia Therapeutics) and Thermo Fisher Scientific collaborated to resolve supply constraints to ensure that patients were able to access Keryx’s proprietary drug through agility and excellent teamwork at all levels of operation.

 

Merck KGaA, Darmstadt, Germany–Bristol-Myers Squibb’s alliance has operated with financial transparency and consistent best practices since its formation in China in the 1990s, a time when the Chinese market was much less accessible.

 

Novartis–Incyte’s decade-long collaboration covers the co-marketing and co-development of an oncology drug in split geographical areas. The alliance has applied best practices across the alliance lifecycle, and led the way for a foundation for a broader alliance mindset in the respective organizations.


Merck & Co. and Sanofi Pasteur built a joint venture for a new drug utilizing a governance model inspired by small, nimble biotech companies to ensure speed and flexibility. The commercialization phase of the new drug so far is very successful.

 

Red Hat completely revamped an alliance training program for its alliance and channel managers, providing a clear learning path for everyone with several checkpoints and feedback options that support managers in their learning. The alliance program has leveraged e-learning and digitization, supported by well-designed management processes.

Cambridge Assessment English teamed up with Future Learn and Crisis Classroom to deliver an online training program for volunteers who help refugees meet refugee needs by focusing on language support. Volunteers (8,000 thus far have signed up) are able to exchange their experience in addition to accessing formal learning modules.

 

Merck KGaA, Darmstadt, Germany developed its Joint Committee Self-Assessment tool after alliance surveys showed that decision-making in the organization’s alliances were too slow. This easily implemented tool helps committees improve their decision making has become standard in the Merck alliance toolkit.

Read the complete press release on PRWeb at http://www.prweb.com/releases/finalists_for_announced_for_2019_asap_alliance_excellence_awards/prweb16099885.htm. Stay tuned for much more coverage of the 2019 finalists and the stories behind their successes on this blog and in Strategic Alliance Quarterly and Monthly magazines.

Tags:  Akebia  Alcon  alliance  ASAP Alliance Excellence Awards  best practices  Bristol-Myers Squibb  Cambridge Assessment English  governance  Incyte  Keryx Biopharmaceuticals  Merck & Co.  Merck KGaA  Novartis  Red Hat  Sanofi Pasteur  Science Applications International Corporation  Thermo Fisher Scientific  toolkit 

Share |
PermalinkComments (0)
 

The C-Suite Takes Front Seat in Lively Panel Discussion at ASAP BioPharma Conference (Part 3)

Posted By Cynthia B. Hanson, Thursday, November 1, 2018
Updated: Wednesday, October 31, 2018

This is a continuation from the panel discussion “Speak My Language: How to Have a High Impact Conversation with the C-suite,” which took place at the 2018 ASAP BioPharma Conference. See Part 1 of this blog post for background information on the panel, which included:

  • James C. Mullen, chairman of the board of directors at Editas Medicine, Inc., who has grown many organizations dependent on partnerships
  •   Samantha Singer, chief operating officer at the Broad Institute, whose organization partners with multiple industries to achieve the Institute’s mission to impact human health throughout the world
  • Alex Waldron, chief commercial officer at Pear Therapeutics, who is highly skilled at bringing in business development and alliance management expertise to grow a company through partnerships

Christine Carberry, CSAP, chief operating officer at Keryx Biopharmaceuticals, moderated the session. At this point in the discussion, Carberry had just prompted panel members to answer the following: “Let’s dig into where things tend to go awry. How do alliance professionals demonstrate their value to the organization? The second half of my question is, what are some of the pitfalls? Where do alliances get in trouble, and how can an alliance manager avoid those pitfalls?” After listening to the responses (see Part 2 of this blog for panelists’ answers), she added her thoughts.

Carberry: Build C-suite-to-C-suite [connections] early on in the relationship. I use to joke that it’s important to have relationships between companies that play golf so the CEOs can get together. You need to be comfortable getting on the phone with them and having a conversation that can go like this: “This is what we’ve done, tried, and this is why it didn’t work.” This is helpful to an executive. We need to implement what will remove barriers and allow us to go forward. The value proposition may have just changed for the companies: That beautiful future might not get created, because we all know divorce is part of the deal. One of the things you will discover as an alliance manager is  you will get people in the organization grumbling about the partner.

Mullen: How many of you inherited a contact, and you were not at the table? [At this point, nearly everyone raised his or her hand while laughter rippled through the room.] Look for the wishy-washy language. Those are the issues that never got resolved during the contract negotiations.

Singer: No matter how good your business development is, the reality is [your perception of the contract] will not match three months later.

Mullen: If you are talking about “stage gate,” make sure it means the same thing between the partners. It may seem really obvious, but it’s not. Make exactly sure of what they are saying.

Carberry: Have clear definitions. For example, “First Patient In.” You may think things are commonly understood, but lawyers say it’s important to make sure definitions are as clear as they possibly can be.

Carberry then fielded an audience question from Jeremy Ahouse, CSAP, vice president alliances, Merus. “A lot of alliance people complain that when they have to bring bad news, the C-suite thinks they only bring problems. How can you do that so that the messenger doesn’t feel like they will get shot?”

Mullen: You need a fairly straight scorecard for the goals of the partnership, and you need a record against that. That way,  it becomes evident that you are making progress. The fact is, [otherwise], you are just raising problems. Check off the problems, and let them know that they talked to you about it, that work was done, and here’s how it got resolved. Keep a high-level scorecard.

Waldron: I agree on the scorecard. And talk about successes, don’t only talk about problems.

Carberry: Everyone is conditioned to success. So if you are doing your job well, you are having those conversations about problems with us.

Waldron: If your company doesn’t have some kind of periodic review, push for that—even if it’s a 15-minute review. Push for that so you can get in front of them. We had a lot of customers, and both the customers and our company didn’t do everything perfectly. But when I had that review of information first, then when they called me up and let me know, 90 percent of the problem was already solved. I knew about it, cared about it, and it got solved.

See parts one and two of this blog and ASAP Media’s ongoing coverage from the 2018 ASAP BioPharma Conference on the ASAP Blog at www.strategic-alliances.org. You will find interviews with conference presenters and other coverage of leadership and strategy, biopharma-tech partnerships, and other trending conference topics in recent and forthcoming editions of Strategic Alliance Magazine and eSAM Plus

Tags:  Alex Waldron  alliance managers  Broad Institute  Christine Carberry  collaborations  c-suite  Editas Medicine  James C. Mullen  Keryx Biopharmaceuticals  partnerships  Pear Therapeutics  Samantha Singer  scorecard 

Share |
PermalinkComments (0)
 

The C-Suite Takes Front Seat in Lively Panel Discussion at ASAP BioPharma Conference (Part 2)

Posted By Cynthia B. Hanson, Wednesday, October 31, 2018

This article continues ASAP Media’s coverage of the panel discussion “Speak My Language: How to Have a High Impact Conversation with the C-suite,” which took place September 25 at the 2018 ASAP BioPharma Conference in Boston. After introducing the panel members (see Part 1 of this blog post for background information on the panelists), Christine Carberry, CSAP, chief operating officer at Keryx Biopharmaceuticals, prompted the panel members to answer the following: “Let’s dig into where things tend to go awry. How do alliance professionals demonstrate their value to the organization? The second half of my question is, what are some of the pitfalls? Where do alliances get in trouble, and how can an alliance manager avoid those pitfalls?”

Samantha Singer, chief operating officer at the Broad Institute: Alliance managers demonstrate their value in their ability to escalate appropriately and bring issues to senior management. We don’t always understand where relationships are going to stumble when we go around the corner. Where I’ve seen situations fall down is when alliance managers think they need to solve problems first; coming to the senior executive when there’s something wrong without ideas for how to solve it. Also, treat the relationship as a relationship. Make sure the transactional doesn’t get in the way of the relationship for you and the entire team. The last point is: Keep the conversations honest. When people are collaborating together, someone usually wants to impress someone else or know more. But we all know, on projects, that is not how you get things done: Tackle problems, and be creative. And make sure that honest dialog really happens.

James C. Mullen, chairman of the board of directors at Editas Medicine, Inc.: Understand whoever is running around the C-suite, they only know so much. You need to decide what they need to know. The tendency is to over-communicate. I’ve received 40-page project reports that I never read. I only care about the problems. Focus on escalating the exceptions. That’s what I need to know about. The best way to get my attention is: Don’t try to tell me everything as if I am on the same level as you are. If you dump those 40 pages in my in-box, they never get read. Escalate it, and escalate it quickly. If there is an issue, highlight it and tell me what the implication of this issue is. I want to hear ideas on how to solve the problem. Finally, I want to know if you need help from me to work on a problem. Those are my four steps. The last thing is: You need to know the details of the contract. And if the realities of the partnership are drifting to someplace else, you need to address that contractually. If they drift too far, then you are in a no-mans land of who-was-supposed-to-do-what.

Alex Waldron, chief commercial officer at Pear Therapeutics: I am empathetic in one area: You are the people who need to implement the contract that has just been written. You’ve got to translate the three million pages into what it means for the company and get that going forward. The quickest way to do this is to create as much transparency as you possibly can with the partners out there. Alliances are like marriages: When you get married, you are star struck. It’s a wonderful idea that is almost never accurate. As both companies grow, the priorities will change over time: Your job is to remind everyone of that. Don’t use the “E” wordEscalate. Try to understand the alliance manager on the other side of the table, and create as much transparency as you can, even if it means saying “I understand why you are saying ‘no’ to me, but I must insist based on this contract….”  Managing the contract is absolutely critical. To ensure the success of the contract is essential to avoid pitfalls.

See recent and forthcoming editions of eSAM Plus and Strategic Alliance Magazine and revisit the ASAP Blog at www.strategic-alliances.org for continuing, comprehensive ASAP Media team coverage of the 2018 ASAP BioPharma Conference. 

Tags:  Alex Waldron  alliance managers  Broad Institute  Christine Carberry  collaborations  c-suite  Editas Medicine  James C. Mullen  Keryx Biopharmaceuticals  partnerships  Pear Therapeutics  Samantha Singer 

Share |
PermalinkComments (0)
 
Page 1 of 2
1  |  2
For more information email us at info@strategic-alliances.org or call +1-781-562-1630